https://www.selleckchem.com/pr....oducts/17-DMAG,Hydro
Moreover, rituximab is associated with a shorter time to obtain a durable remission in aTTP and a faster time (15 days) to final ADAMTS13 activity recovery 10%. To our knowledge, this is the first case of early discontinuation of caplacizumab in a patient allergic to PEX by actively monitoring ADAMTS13 activity, allowing optimization of healthcare resources during COVID-19 pandemic. Patients with major depression present with an increased serum insulin-like growth factor-1 (IGF-1) concentration. However, the longi
Beğen
Yorum Yap
Paylaş
